Lucira Health to Participate in Bank of America 2022 Healthcare Conference
Lucira Health, a medical technology company, will present at the Bank of America 2022 Healthcare Conference on May 11, 2022, at 11:00 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lucira Health, a medical technology company, will present at the Bank of America 2022 Healthcare Conference on May 11, 2022, at 11:00 PM ET. The event can be accessed via a live and archived webcast on Lucira's website. Known for its innovative infectious disease test kits, Lucira focuses on providing lab-quality molecular testing in a user-friendly, portable format. The company is also developing new diagnostic tests, including a combined test for COVID-19 and Flu. Visit www.lucirahealth.com for more details.
Details
News Market Reaction – LHDX
The recorded move for LHDX in the trading session of this news was +1.97%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will participate in the Bank of America 2022 Healthcare Conference on May 11th, 2022, at 11:00pm ET.
Lucira’s management is scheduled to present at the Bank of America 2022 Healthcare Conference on May 11th, 2022, at 11:00pm ET. A live and archived webcast of the event can be accessed through the Events and Presentations page of the Lucira website.
About Lucira Health
Lucira is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests. Lucira's testing platform produces lab quality molecular testing in a single-use, consumer-friendly, palm-size test kit powered by two AA batteries. Lucira designed its test kits to provide accurate, reliable, and on-the-spot molecular test results anywhere and at any time.
Beyond its COVID-19 tests, Lucira is working on new diagnostic tests including a single test for COVID-19 & Flu as well as other infectious diseases. For more information, visit www.lucirahealth.com.
Investor Contact
Greg Chodaczek
Investorrelations@lucirahealth.com
332-895-3230
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.